RxDoctor Payments Data

Maria Ortega

Adult Health · Miami, FLNPI 1023313152

Payments from drug & device makers

$949in general payments, 2019–2025

Across 48 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$219
  • GSK$159
  • AstraZeneca$111
  • Abbott$72
  • Arbor Pharmaceuticals, Inc.$58
  • Sunovion Pharmaceuticals Inc.$58
  • plus $273 from 8 others

What the payments were for

  • Food & beverage$75980%
  • Education$19020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$949 in reported general payments places this provider in the 60th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$12,395
Medicare patients
30
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide176$183,489
EliquisApixaban94$94,956
MounjaroTirzepatide68$72,151
ProliaDenosumab33$56,957
JanuviaSitagliptin Phosphate27$42,530
MyrbetriqMirabegron58$34,463
XareltoRivaroxaban46$33,860
FarxigaDapagliflozin Propanediol34$32,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,294
TradjentaLinagliptin25$27,607
JardianceEmpagliflozin19$26,393
JanumetSitagliptin Phos/Metformin Hcl31$25,073
TrulicityDulaglutide22$21,307
LinzessLinaclotide28$19,106
VascepaIcosapent Ethyl39$14,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$42$193,880187 claims
AmgenProlia$19$56,95733 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$111$48,91581 claims
Astellas Pharma US IncMyrbetriq$219$34,46358 claims
GSKTrelegy Ellipta$159$28,29440 claims
AbbVieLinzess$39$19,10628 claims
NovartisEntresto$33$10,69416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,237 adult health providers in Florida.

Other adult health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →